TMEM214: A Transmembrane Protein Target for Drug Development and Cancer Treatment

Target Name: TMEM214

NCBI ID: G54867

TMEM214

TMEM214: A Transmembrane Protein Target for Drug Development and Cancer Treatment

TMEM214 (Transmembrane protein 214) is a gene that encodes a protein located at the cell membrane, which plays an essential role in various cellular processes. TMEM214 has been identified as a potential drug target and biomarker for various diseases, including cancer. This article will provide an overview of TMEM214, its potential drug targets, and its potential in cancer treatment.

Overview of TMEM214

TMEM214 is a 21 kDa transmembrane protein that is expressed in various tissues, including brain, heart, lungs, and gastrointestinal tract. TMEM214 is composed of 116 amino acid residues and has a calculated pI of 6.9. TMEM214 is primarily expressed in the cytoplasm and is also found in the endoplasmic reticulum and in the secretory pathway. TMEM214 is involved in various cellular processes, including cell signaling, adhesion, and migration.

Potential Drug Targets

TMEM214 has been identified as a potential drug target due to its unique structure and various functions. TMEM214 can interact with various signaling molecules, including TGF-β1, NF-kappa-B, and Hedgehog. TMEM214 has also been shown to play a role in cell adhesion and migration, making it an attractive target for drugs that are designed to modulate these processes. Additionally, TMEM214 has been shown to be involved in the regulation of ion channels, which could make it an attractive target for drugs that target ion channels in cancer cells.

TMEM214 as a Biomarker

TMEM214 has also been identified as a potential biomarker for various diseases, including cancer. The expression of TMEM214 has been shown to be elevated in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, studies have shown that TMEM214 has been associated with cancer progression and poor prognosis. This suggests that TMEM214 may be a useful biomarker for cancer diagnosis and treatment.

Drug Development

Several compounds have been shown to interact with TMEM214 and to display potential drug properties. One of the most promising compounds is a small molecule inhibitor of the protein kinase PDK4, which has been shown to interact with TMEM214 and inhibit its activity. The inhibitor has been shown to be effective in preclinical studies against various types of cancer, including breast, ovarian, and colorectal cancer.

Another compound that has been shown to interact with TMEM214 is a peptide derived from the immune system's MHC class I region. The peptide has been shown to be effective in preclinical studies against various types of cancer, including breast, ovarian, and colorectal cancer.

Conclusion

TMEM214 is a transmembrane protein that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and various functions make it an attractive target for drugs that can modulate its activity. Further studies are needed to determine the full potential of TMEM214 as a drug and to develop effective biomarkers for its various functions.

Protein Name: Transmembrane Protein 214

Functions: Critical mediator, in cooperation with CASP4, of endoplasmic reticulum-stress induced apoptosis. Required or the activation of CASP4 following endoplasmic reticulum stress

The "TMEM214 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM214 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets